Back to List View Graph View

Dexamethasone

Dexamethasone is a synthetic glucocorticoid drug used clinically for its anti-inflammatory, immunosuppressive, and antineoplastic effects.

Where the papers sit

46 papers from the last 6 months study dexamethasone directly · updated from PubMed 14 Nov 2026

  • Advanced Drug Delivery Systems

    Responsive biomaterials are moving drug delivery toward sustained, site-specific and sequential release. MMP-responsive microgels, microneedles, transmucosal nanoparticles, hydrogels, neural coatings and engineered microparticles address local retention and controlled co-delivery. Cross-linking, pH/ROS triggers, receptor interactions and morphology tuning recur as design strategies. Most evidence remains preclinical, with stability, tissue penetration and therapeutic performance still needing validation beyond formulation studies.

    12 papers · 26.1%

  • Multiple Myeloma Treatment

    Combination regimens are moving toward deeper, more durable responses in newly diagnosed and relapsed multiple myeloma. Daratumumab added to VRd, alongside selinexor, mezigdomide, carfilzomib, ixazomib and melflufen, is being tested across transplant eligibility, renal impairment and heavily pretreated disease. Minimal residual disease, progression-free survival and renal recovery recur as key endpoints. Results support intensified therapy, but single-arm and retrospective data still require confirmation without excess toxicity.

    11 papers · 23.9%

  • Corticosteroid Effects and Safety

    Dexamethasone use is being refined to preserve antiemetic, antiallergic and anti-inflammatory benefit while limiting hyperglycaemia, infection and other steroid toxicity. Reduced premedication is being tested with weekly paclitaxel, while steroid-sparing regimens address nausea during cervical chemoradiotherapy. In cancer care, prophylaxis also targets opioid-induced vomiting and enfortumab vedotin–pembrolizumab skin toxicity, with neurokinin-1 antagonist coadministration linked to diabetes risk. Ocular implants, fibrosis therapies and viral-pneumonia rescue broaden the set beyond supportive care, so no single direction dominates.

    11 papers · 23.9%

  • Inflammation-Targeted Nanotherapies

    Anti-inflammatory treatment is shifting toward localized, multifunctional delivery that combines cytokine suppression with redox control. Lipid nanoparticles, microneedles and cerium-luteolin systems target TNF-α, IL-6, reactive oxygen species and tissue-specific inflammation. Dexamethasone is repeatedly paired with siTNF-α or photobiomodulation, while HDAC6 inhibition addresses steroid-induced muscle atrophy. Evidence remains largely cellular or preclinical, leaving durability, delivery safety and clinical translation open.

    6 papers · 13%

  • Others — Retinal and Perioperative Steroids

    Retinal steroid treatment is being refined through OCT biomarkers, implant use during vitreoretinal surgery and escalation strategies for cystoid macular edema. Anatomical response, reinjection burden, intraocular pressure and cataract risk recur as practical endpoints. The cluster also contains dexamethasone suppression testing and day-of-surgery glycaemic management, which do not form a clear therapeutic direction with the eye studies. It therefore reflects ophthalmic management alongside perioperative endocrine and infection-control questions.

    6 papers · 13%

NEW DIRECTION

Dexamethasone functions as a structural modulator of a drug-delivery hydrogel rather than solely as its therapeutic payload

The keratin/ι-carrageenan hydrogel model uses dexamethasone as a dual-functional material component: supramolecular hydrogen bonding makes it an interfacial sliding agent that reduces interchain friction within densely crosslinked networks, while the hydrogel is designed for controlled drug delivery 42785881Sep. This assigns dexamethasone a role outside the set’s usual categories of anti-inflammatory treatment, prophylactic medication, or released drug: it directly changes the carrier’s network behavior and printability, expanding its function from pharmacologic agent to rheological and structural modifier.

dexamethasone chemical structure

Papers

The 46 papers from the last 6 months that study dexamethasone directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Advanced Drug Delivery Systems (12)
  1. Rheology-guided experimental design of dynamically crosslinked keratin/ι-carrageenan hydrogels as potential drug delivery systems. Carbohydrate polymers · 24 Sept 2026 PMID 42785881
  2. H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids. Cell stem cell · 16 Sept 2026 PMID 42748922
  3. Cross-Talk Between Histamine H2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment. Pharmacology research & perspectives · 15 Sept 2026 PMID 42736631
  4. Poly(l-glutamic Acid)-Based Microgels with Long-Term Synergistic Lubrication and MMP-Responsive Anti-Inflammatory Delivery for Osteoarthritis Therapy. Biomacromolecules · 14 Sept 2026 PMID 42734288
  5. Evaluation of Method "Whiteness" in the Stability Analysis of Dexamethasone and PVP-I Ophthalmic Suspensions: Synergizing LC-MS/MS, In Silico Toxicology, and AGREE/GAPI Metrics. Biomedical chromatography : BMC · 17 Aug 2026 PMID 42608054
  6. pH/ROS dual-responsive injectable hydrogel based on an oxidized hyaluronic acid/carboxymethyl chitosan-phenylboronic acid dynamic network for rheumatoid arthritis therapy. International journal of biological macromolecules · 24 Jul 2026 PMID 42498194
  7. Dual-functionalized GelFuMA hydrogel with sequential crosslinking for tunable mechanics and controlled drug release. Biomaterials science · 8 Jul 2026 PMID 42417823
  8. Harnessing Hydrogel Interaction with Functional Polymeric Nanoparticles for Sustained Co-Delivery of Therapeutics. ACS biomaterials science & engineering · 16 Jun 2026 PMID 42301751
  9. Study on transdermal delivery system of sulforaphane chitosan nanoparticles based on methacryloylated chitosan microneedles: application in the treatment of irritant contact dermatitis. International journal of pharmaceutics · 14 Jun 2026 PMID 42289208
  10. Electroactive nanostructured polypyrrole coatings with on-demand drug release for immunomodulation of neural electrode interfaces. Colloids and surfaces. B, Biointerfaces · 13 Jun 2026 PMID 42287830
  11. Salivary Enzyme-Responsive Switching Nanoparticles Overcoming Diffusion and Absorption Barriers for Transmucosal Delivery. ACS applied materials & interfaces · 3 Jun 2026 PMID 42233472
  12. Engineered microparticle morphology for enhanced intestinal retention in oral drug delivery. Acta biomaterialia · 30 May 2026 PMID 42217660
Multiple Myeloma Treatment (11)
  1. Renal rescue in myeloma: How deep does the hematologic response need to be? Med (New York, N.Y.) · 9 Oct 2026 PMID 42854676
  2. Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003). Med (New York, N.Y.) · 9 Sept 2026 PMID 42716009
  3. Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study. Trials · 28 Aug 2026 PMID 42661196
  4. Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of medicine · 3 Aug 2026 PMID 42544613
  5. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
  6. Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clinical and translational science · 30 Jun 2026 PMID 42374568
  7. Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia · 18 Jun 2026 PMID 42315418
  8. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet (London, England) · 14 Jun 2026 PMID 42289183
  9. Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. Clinical lymphoma, myeloma & leukemia · 10 Jun 2026 PMID 42270486
  10. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
  11. The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749
Corticosteroid Effects and Safety (11)
  1. Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 7 Nov 2026 PMID 42998233
  2. Incidence of Nausea and Vomiting in Patients With Cervical Cancer Undergoing Chemoradiotherapy With Steroid-Sparing. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957248
  3. Association of co-administration of neurokinin-1 receptor antagonists and dexamethasone with new-onset diabetes in patients receiving chemotherapy: a retrospective cross-sectional study using health claims database in Japan. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 Oct 2026 PMID 42955428
  4. Phenylboronate hydrogel for administration route tailored dual-drug delivery to anterior and posterior ocular segments. Journal of controlled release : official journal of the Controlled Release Society · 14 Oct 2026 PMID 42874931
  5. Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. International journal of clinical oncology · 3 Sept 2026 PMID 42687064
  6. A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model. Molecular biomedicine · 2 Sept 2026 PMID 42684552
  7. Efficacy of Corticosteroid Therapy on Neurological Outcomes in Near-Hanging Patients With Altered Sensorium: Protocol for a Multicenter, Double-Blinded, Placebo-Controlled, Randomized Trial (CHANGING Trial). JMIR research protocols · 25 Aug 2026 PMID 42640135
  8. Steroid-loaded Avidin-Nucleic-Acid-Nano-Assemblies reduce hepatic fibrosis modulating Kupffer cells in primary biliary cholangitis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 22 Jul 2026 PMID 42486017
  9. Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 Jun 2026 PMID 42371187
  10. The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial. British journal of anaesthesia · 16 Jun 2026 PMID 42303515
  11. Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants for Non-Infectious Posterior-Segment Uveitis: 12-Month Real-World Outcomes. Ocular immunology and inflammation · 26 May 2026 PMID 42188201
Inflammation-Targeted Nanotherapies (6)
  1. Dissolving Microneedles Loaded with Lipid Nanoparticles for Co-Delivery of siTNF-α and Dexamethasone as a Dual-Action Therapy for Psoriasis. ACS applied materials & interfaces · 14 Sept 2026 PMID 42735507
  2. HDAC6 inhibition alleviates dexamethasone-induced skeletal muscle atrophy and enhances UCP3-associated redox homeostasis. Free radical biology & medicine · 5 Aug 2026 PMID 42556488
  3. Effects of photobiomodulation, alone or combined with dexamethasone, on cellular metabolic activity and inflammatory markers in LPS/IFN-γ-stimulated J774 macrophages. Lasers in medical science · 2 Aug 2026 PMID 42543442
  4. Reverse-Engineered Lipid Nanoparticles Harness Protein Corona Formation for Cytokine Sequestration and Combination Immunomodulatory Therapy. Small (Weinheim an der Bergstrasse, Germany) · 29 Jul 2026 PMID 42522898
  5. Coordination-driven self-assembly of antioxidative and anti-inflammatory cerium-luteolin nanoparticles for effective treatment of ocular alkali burns. Journal of materials chemistry. B · 16 Jun 2026 PMID 42301120
  6. Attenuation of LPS-induced inflammatory responses in J774A.1 macrophages by phenylpropanoids and ursane triterpenes from Lavandula coronopifolia Poir. Scientific reports · 24 May 2026 PMID 42178365
Others — Retinal and Perioperative Steroids (6)
  1. Baseline OCT Biomarkers Associated with Anatomical Response and Long-Term Reinjection Burden in Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant. International ophthalmology · 13 Nov 2026 PMID 43024117
  2. Dexamethasone implant in vitreoretinal surgery for diabetic retinal detachment: A retrospective comparative study. Indian journal of ophthalmology · 28 Oct 2026 PMID 42949081
  3. Real-world management of chronic pseudophakic cystoid macular oedema: a descriptive case series of treatment timelines and escalation patterns. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 25 Aug 2026 PMID 42640292
  4. Variation and knowledge translation gaps in day-of-surgery glycaemic management by anaesthesiologists: a qualitative exploration of a quality gap in Canadian hospitals. BMJ open · 15 Jul 2026 PMID 42457420
  5. Bacterial Communities Identified by Standard Culture and 16S rRNA Amplicon Sequencing in Ophthalmic Preservative-Free Dexamethasone SP Used in Canine Cataract Surgery. Veterinary ophthalmology · 15 Jun 2026 PMID 42290185
  6. Reliability of the Overnight Dexamethasone Suppression Test in Patients Undergoing Bariatric Surgery. Obesity surgery · 23 May 2026 PMID 42176158

By study type

Clinical trials (8)
  1. Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 7 Nov 2026 PMID 42998233
  2. Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003). Med (New York, N.Y.) · 9 Sept 2026 PMID 42716009
  3. Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study. Trials · 28 Aug 2026 PMID 42661196
  4. Efficacy of Corticosteroid Therapy on Neurological Outcomes in Near-Hanging Patients With Altered Sensorium: Protocol for a Multicenter, Double-Blinded, Placebo-Controlled, Randomized Trial (CHANGING Trial). JMIR research protocols · 25 Aug 2026 PMID 42640135
  5. Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia · 18 Jun 2026 PMID 42315418
  6. The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial. British journal of anaesthesia · 16 Jun 2026 PMID 42303515
  7. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet (London, England) · 14 Jun 2026 PMID 42289183
  8. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
Observational studies and case reports (11)
  1. Baseline OCT Biomarkers Associated with Anatomical Response and Long-Term Reinjection Burden in Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant. International ophthalmology · 13 Nov 2026 PMID 43024117
  2. Incidence of Nausea and Vomiting in Patients With Cervical Cancer Undergoing Chemoradiotherapy With Steroid-Sparing. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957248
  3. Association of co-administration of neurokinin-1 receptor antagonists and dexamethasone with new-onset diabetes in patients receiving chemotherapy: a retrospective cross-sectional study using health claims database in Japan. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 Oct 2026 PMID 42955428
  4. Dexamethasone implant in vitreoretinal surgery for diabetic retinal detachment: A retrospective comparative study. Indian journal of ophthalmology · 28 Oct 2026 PMID 42949081
  5. Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. International journal of clinical oncology · 3 Sept 2026 PMID 42687064
  6. Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of medicine · 3 Aug 2026 PMID 42544613
  7. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
  8. Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clinical and translational science · 30 Jun 2026 PMID 42374568
  9. Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 Jun 2026 PMID 42371187
  10. Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. Clinical lymphoma, myeloma & leukemia · 10 Jun 2026 PMID 42270486
  11. Reliability of the Overnight Dexamethasone Suppression Test in Patients Undergoing Bariatric Surgery. Obesity surgery · 23 May 2026 PMID 42176158
Human data, design not indexed (3)
  1. Renal rescue in myeloma: How deep does the hematologic response need to be? Med (New York, N.Y.) · 9 Oct 2026 PMID 42854676
  2. Evaluation of Method "Whiteness" in the Stability Analysis of Dexamethasone and PVP-I Ophthalmic Suspensions: Synergizing LC-MS/MS, In Silico Toxicology, and AGREE/GAPI Metrics. Biomedical chromatography : BMC · 17 Aug 2026 PMID 42608054
  3. Variation and knowledge translation gaps in day-of-surgery glycaemic management by anaesthesiologists: a qualitative exploration of a quality gap in Canadian hospitals. BMJ open · 15 Jul 2026 PMID 42457420
Preclinical: animal, cell and lab studies (18)
  1. Phenylboronate hydrogel for administration route tailored dual-drug delivery to anterior and posterior ocular segments. Journal of controlled release : official journal of the Controlled Release Society · 14 Oct 2026 PMID 42874931
  2. Rheology-guided experimental design of dynamically crosslinked keratin/ι-carrageenan hydrogels as potential drug delivery systems. Carbohydrate polymers · 24 Sept 2026 PMID 42785881
  3. Cross-Talk Between Histamine H2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment. Pharmacology research & perspectives · 15 Sept 2026 PMID 42736631
  4. Poly(l-glutamic Acid)-Based Microgels with Long-Term Synergistic Lubrication and MMP-Responsive Anti-Inflammatory Delivery for Osteoarthritis Therapy. Biomacromolecules · 14 Sept 2026 PMID 42734288
  5. A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model. Molecular biomedicine · 2 Sept 2026 PMID 42684552
  6. HDAC6 inhibition alleviates dexamethasone-induced skeletal muscle atrophy and enhances UCP3-associated redox homeostasis. Free radical biology & medicine · 5 Aug 2026 PMID 42556488
  7. Effects of photobiomodulation, alone or combined with dexamethasone, on cellular metabolic activity and inflammatory markers in LPS/IFN-γ-stimulated J774 macrophages. Lasers in medical science · 2 Aug 2026 PMID 42543442
  8. pH/ROS dual-responsive injectable hydrogel based on an oxidized hyaluronic acid/carboxymethyl chitosan-phenylboronic acid dynamic network for rheumatoid arthritis therapy. International journal of biological macromolecules · 24 Jul 2026 PMID 42498194
  9. Steroid-loaded Avidin-Nucleic-Acid-Nano-Assemblies reduce hepatic fibrosis modulating Kupffer cells in primary biliary cholangitis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 22 Jul 2026 PMID 42486017
  10. Dual-functionalized GelFuMA hydrogel with sequential crosslinking for tunable mechanics and controlled drug release. Biomaterials science · 8 Jul 2026 PMID 42417823
  11. Harnessing Hydrogel Interaction with Functional Polymeric Nanoparticles for Sustained Co-Delivery of Therapeutics. ACS biomaterials science & engineering · 16 Jun 2026 PMID 42301751
  12. Coordination-driven self-assembly of antioxidative and anti-inflammatory cerium-luteolin nanoparticles for effective treatment of ocular alkali burns. Journal of materials chemistry. B · 16 Jun 2026 PMID 42301120
  13. Bacterial Communities Identified by Standard Culture and 16S rRNA Amplicon Sequencing in Ophthalmic Preservative-Free Dexamethasone SP Used in Canine Cataract Surgery. Veterinary ophthalmology · 15 Jun 2026 PMID 42290185
  14. Study on transdermal delivery system of sulforaphane chitosan nanoparticles based on methacryloylated chitosan microneedles: application in the treatment of irritant contact dermatitis. International journal of pharmaceutics · 14 Jun 2026 PMID 42289208
  15. Electroactive nanostructured polypyrrole coatings with on-demand drug release for immunomodulation of neural electrode interfaces. Colloids and surfaces. B, Biointerfaces · 13 Jun 2026 PMID 42287830
  16. Salivary Enzyme-Responsive Switching Nanoparticles Overcoming Diffusion and Absorption Barriers for Transmucosal Delivery. ACS applied materials & interfaces · 3 Jun 2026 PMID 42233472
  17. Engineered microparticle morphology for enhanced intestinal retention in oral drug delivery. Acta biomaterialia · 30 May 2026 PMID 42217660
  18. Attenuation of LPS-induced inflammatory responses in J774A.1 macrophages by phenylpropanoids and ursane triterpenes from Lavandula coronopifolia Poir. Scientific reports · 24 May 2026 PMID 42178365
Unclassified: not yet indexed with MeSH (6)
  1. H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids. Cell stem cell · 16 Sept 2026 PMID 42748922
  2. Dissolving Microneedles Loaded with Lipid Nanoparticles for Co-Delivery of siTNF-α and Dexamethasone as a Dual-Action Therapy for Psoriasis. ACS applied materials & interfaces · 14 Sept 2026 PMID 42735507
  3. Real-world management of chronic pseudophakic cystoid macular oedema: a descriptive case series of treatment timelines and escalation patterns. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 25 Aug 2026 PMID 42640292
  4. Reverse-Engineered Lipid Nanoparticles Harness Protein Corona Formation for Cytokine Sequestration and Combination Immunomodulatory Therapy. Small (Weinheim an der Bergstrasse, Germany) · 29 Jul 2026 PMID 42522898
  5. Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants for Non-Infectious Posterior-Segment Uveitis: 12-Month Real-World Outcomes. Ocular immunology and inflammation · 26 May 2026 PMID 42188201
  6. The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749